JP2019513412A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513412A5
JP2019513412A5 JP2018568171A JP2018568171A JP2019513412A5 JP 2019513412 A5 JP2019513412 A5 JP 2019513412A5 JP 2018568171 A JP2018568171 A JP 2018568171A JP 2018568171 A JP2018568171 A JP 2018568171A JP 2019513412 A5 JP2019513412 A5 JP 2019513412A5
Authority
JP
Japan
Prior art keywords
cells
nanoparticles
paramagnetic
expanded
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018568171A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513412A (ja
JP7016098B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/022663 external-priority patent/WO2017161092A1/en
Publication of JP2019513412A publication Critical patent/JP2019513412A/ja
Publication of JP2019513412A5 publication Critical patent/JP2019513412A5/ja
Application granted granted Critical
Publication of JP7016098B2 publication Critical patent/JP7016098B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018568171A 2016-03-16 2017-03-16 抗原特異的t細胞の生成 Active JP7016098B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662309234P 2016-03-16 2016-03-16
US62/309,234 2016-03-16
PCT/US2017/022663 WO2017161092A1 (en) 2016-03-16 2017-03-16 Production of antigen-specific t-cells

Publications (3)

Publication Number Publication Date
JP2019513412A JP2019513412A (ja) 2019-05-30
JP2019513412A5 true JP2019513412A5 (cg-RX-API-DMAC7.html) 2020-04-23
JP7016098B2 JP7016098B2 (ja) 2022-02-21

Family

ID=59850933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018568171A Active JP7016098B2 (ja) 2016-03-16 2017-03-16 抗原特異的t細胞の生成

Country Status (11)

Country Link
US (2) US20200291381A1 (cg-RX-API-DMAC7.html)
EP (1) EP3445399A4 (cg-RX-API-DMAC7.html)
JP (1) JP7016098B2 (cg-RX-API-DMAC7.html)
KR (1) KR102470979B1 (cg-RX-API-DMAC7.html)
CN (1) CN109475620A (cg-RX-API-DMAC7.html)
AU (1) AU2017233035B2 (cg-RX-API-DMAC7.html)
CA (1) CA3017615A1 (cg-RX-API-DMAC7.html)
IL (1) IL261710A (cg-RX-API-DMAC7.html)
RU (2) RU2021107053A (cg-RX-API-DMAC7.html)
SG (2) SG10202008210XA (cg-RX-API-DMAC7.html)
WO (1) WO2017161092A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7054397B2 (ja) * 2016-06-27 2022-04-13 ジュノー セラピューティクス インコーポレイテッド Mhc-e拘束性エピトープ、結合分子ならびに関連する方法および使用
BR112020005552A2 (pt) * 2017-09-20 2020-10-27 Neximmune, Inc. composições de células compreendendo células t específicas de antígeno para terapia adotiva
CN111787930B (zh) * 2017-10-06 2024-12-20 芝加哥大学 针对癌症特异性抗原对t淋巴细胞的筛选
AU2019291071B2 (en) * 2018-06-20 2026-01-08 Danmarks Tekniske Universitet Scaffolds with stabilized MHC molecules for immune-cell manipulation
AU2019345052B2 (en) * 2018-09-19 2025-09-04 FUJIFILM Cellular Dynamics, Inc. Protein L for activation and expansion of chimeric antigen receptor-modified immune cells
CN109136276A (zh) * 2018-09-30 2019-01-04 北京鼎成肽源生物技术有限公司 一种rfft2细胞的构建方法
JP7863702B2 (ja) 2018-11-08 2026-05-22 セルキュア インコーポレイテッド 表現型特性が向上したt細胞組成物
WO2021173847A1 (en) * 2020-02-27 2021-09-02 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Cobra1/nelf-b as a booster for efficacy of cd8+ t cell-based therapy
EP4172352A4 (en) * 2020-06-26 2024-07-03 The Johns Hopkins University Adaptive nanoparticle platforms for high throughput expansion and detection of antigen-specific t cells
WO2022125901A1 (en) * 2020-12-11 2022-06-16 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
JP2024510244A (ja) * 2021-03-17 2024-03-06 ミルテニー バイオテック ベー.フェー. ウント コー. カー・ゲー 抗原特異的活性化及びcar t細胞の増殖のための人工標的
WO2023060217A1 (en) * 2021-10-08 2023-04-13 Baylor College Of Medicine Transgenic t cell receptors targeting neoantigens for diagnosis, prevention, and/or treatment of hematological cancers
WO2023144275A1 (en) * 2022-01-28 2023-08-03 Katholieke Universiteit Leuven Actuation of organoids by magnetic nanoparticles
DE102022132082B4 (de) * 2022-12-02 2024-08-08 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung.
WO2026035444A1 (en) * 2024-07-24 2026-02-12 Cellkure, Inc. Methods for identifying functional neoantigens and their use in cancer immunotherapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
JPH11507843A (ja) 1996-03-28 1999-07-13 ザ・ジョンズ・ホプキンス・ユニバーシティー タンパク質の可溶性二価および多価ヘテロ二量体類縁体
US6140113A (en) 1996-03-28 2000-10-31 The Johns Hopkins University Polynucleotides encoding molecular complexes which modify immune responses
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
CA2359636A1 (en) 1999-01-22 2000-07-27 Andrew W. Taylor Activation of regulatory t cells by alpha-melanocyte stimulating hormone
US6746670B2 (en) 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
RU2311920C2 (ru) * 2000-09-20 2007-12-10 Корикса Корпорейшн Композиции и способы для лечения и диагностики рака легких
US6670146B2 (en) 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods
US20030049696A1 (en) 2001-06-07 2003-03-13 Norment Anne M. Regulatory T cells and uses thereof
JP2003102471A (ja) 2001-10-01 2003-04-08 Kirin Brewery Co Ltd 調節性t細胞の分化誘導・増殖促進方法
WO2004104185A1 (en) * 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
AT503861B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
US20120128656A1 (en) * 2008-05-02 2012-05-24 Immunovative Therapies, Ltd. Vaccine compositions and methods
CN102168066A (zh) * 2011-01-31 2011-08-31 浙江大学 体外诱导乙型肝炎病毒特异性细胞毒性t淋巴细胞的方法
US10758487B2 (en) 2011-12-09 2020-09-01 The Johns Hopkins University Artificial antigen presenting cells having a defined and dynamic shape
KR20210149195A (ko) * 2012-07-13 2021-12-08 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 형질도입된 t 세포의 투여 적합성을 평가하는 방법
MX376790B (es) * 2013-03-14 2025-03-07 Univ Johns Hopkins Células presentadoras de antígeno artificiales de nanoescala.
AU2014302784B2 (en) 2013-06-24 2020-01-23 Neximmune Compositions and methods for immunotherapy
US11807675B2 (en) * 2013-10-03 2023-11-07 The University Of Maryland, Baltimore Nanoparticle based artificial antigen presenting cell mediated activation of NKT cells
US10066265B2 (en) * 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
KR20160016725A (ko) * 2014-08-05 2016-02-15 주식회사 유영제약 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포
JP6743022B2 (ja) 2014-12-24 2020-08-19 ネクシミューン インコーポレイテッド 免疫療法のためのナノ粒子組成物及び方法

Similar Documents

Publication Publication Date Title
AU2022287548B2 (en) T Cells For Expression Of Chimeric Antigen Receptors And Other Receptors
Huff et al. The evolving role of CD8+ CD28− immunosenescent T cells in cancer immunology
US20250002850A1 (en) Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
Parent et al. Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection
Somanchi et al. Expansion, purification, and functional assessment of human peripheral blood NK cells
Lässer et al. Isolation and characterization of RNA-containing exosomes
EP3188740B1 (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
JP2016509839A5 (cg-RX-API-DMAC7.html)
JP2016509840A5 (cg-RX-API-DMAC7.html)
Voskamp et al. Immunotherapy in medulloblastoma: current state of research, challenges, and future perspectives
JP2016539929A5 (cg-RX-API-DMAC7.html)
Moreira-Teixeira et al. Rapamycin combined with TGF-β converts human invariant NKT cells into suppressive Foxp3+ regulatory cells
JP2013177430A5 (cg-RX-API-DMAC7.html)
WO2018175408A8 (en) METHODS AND COMPOSITIONS FOR MODULATION OF IMMUNE CELLS
Dohnal et al. Comparative evaluation of techniques for the manufacturing of dendritic cell‐based cancer vaccines
JP2013523841A5 (cg-RX-API-DMAC7.html)
RU2018136203A (ru) Получение антигенспецифических t-клеток
JP2012521769A5 (cg-RX-API-DMAC7.html)
Watts et al. Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS®(v2· 1) and Isolex® 300i (v2· 5) clinical scale devices
Stockinger et al. CD4 T-cell memory
Lesterhuis et al. PD-L2 is predominantly expressed by Th2 cells
van Bruggen et al. Overcoming the hurdles of autologous T-cell-based therapies in B-cell non-hodgkin lymphoma
Esmaeili et al. Spiky gold nanoparticles, a nanoscale approach to enhanced ex vivo T-cell activation
Edri et al. Nicotinamide-expanded allogeneic natural killer cells with CD38 deletion, expressing an enhanced CD38 chimeric antigen receptor, target multiple myeloma cells
WO2005094353A2 (en) Methods for production of regulatory t cells and uses thereof